Generalized Anxiety Disorder Clinical Trial
Official title:
Improving Outcomes for Adults With Generalized Anxiety Disorder: Combining Cognitive-Behavioral Treatment and Interpretation Modification Training
Generalized Anxiety Disorder (GAD) is a condition characterized by chronic and excessive worry and anxiety. Our group has developed a cognitive-behavioural treatment (CBT) for GAD that has been tested in four previous clinical trials. The findings show that 60 to 70% of affected individuals attain GAD remission and that 50 to 55% achieve high endstate functioning following the treatment. Although these numbers are encouraging, there remain a considerable proportion of individuals who do not fully benefit from treatment. In our most recent CIHR-funded treatment study, we assessed the impact of information processing on the efficacy of CBT for GAD. Our findings show: a) that the tendency to negatively interpret ambiguous information at pre-treatment was associated with greater GAD symptoms at post-treatment; and b) that patients who were less successful at changing their negative interpretation style were also less responsive to CBT. Given that computerized interpretation modification training has been shown to be effective for decreasing the negative interpretation style of anxious individuals, the goal of the current proposal is to determine whether such training can augment the efficacy of CBT for adults with GAD. A total of 138 individuals with a primary diagnosis of GAD will be randomly allocated to one of two conditions: a) CBT plus interpretation modification training or b) CBT plus non-active training. CBT will consist of 14 weekly sessions, with interpretation modification training (or non-active training) administered prior to each session. Measures of GAD symptoms, psychopathology, cognitive vulnerability, and interpretation style will be administered at pre-, mid-, and post-treatment, as well as at 6- and 12-month follow-ups. The proposed study will provide information about the efficacy, clinical usefulness, and mechanisms of interpretation modification training in combination with CBT.
Generalized Anxiety Disorder (GAD) is characterized by excessive and uncontrollable worry and
anxiety. In Canada, the point prevalence of GAD is 3 to 4%, and the personal and social costs
of GAD are well documented. Over the past decade, new cognitive-behavioural treatments have
been developed for GAD. Our group has also developed a cognitive-behavioural treatment (CBT)
protocol for GAD, which focuses on intolerance of uncertainty. There are now four published
randomized clinical trials of the treatment, with results suggesting that it is more
efficacious than wait-list control, supportive therapy, and applied relaxation. Although
these results are encouraging, 30 to 40% of affected individuals do not attain diagnostic
remission and 45 to 50% do not achieve high endstate functioning at post-treatment.
In an effort to augment the efficacy of the treatment protocol for GAD, we have recently
examined a broad range of demographic and clinical variables that might predict a limited
response to treatment. The results of our analyses suggest that a particular type of
cognitive bias plays a key role in determining treatment response. Specifically, patients
with a particularly negative interpretation style (i.e., the tendency to negatively interpret
ambiguous information) have a greater probability of not attaining remission following CBT
(they also show less improvement on other indicators of treatment outcome). In addition,
change in interpretation style appears to mediate change in GAD symptoms over the course of
CBT. Thus, the data suggest that treatment efficacy could be increased by adding training
strategies that specifically address negatively biased interpretations of ambiguous
information. Recently, a number of experimental investigations have shown that the tendency
to negatively interpret ambiguous information can be decreased using computerized
interpretation modification training. In fact, the data show that such changes can be
maintained over time, can generalize to new situations, and can lead to corresponding changes
in GAD symptoms and anxiety proneness. Thus, it appears that computerized interpretation
modification training has the potential to increase the efficacy of current CBT protocols by
directly targeting and decreasing the tendency to negatively interpret ambiguous information.
The proposed randomized clinical trial addresses the following question: Can computerized
interpretation modification training augment the efficacy of CBT for GAD? A total of 138
individuals with a primary diagnosis of GAD will be randomly allocated to one of two
conditions: a) CBT plus interpretation modification training (CBT+IMT) or b) CBT plus
non-active training (CBT+NA). CBT will consist of 14 weekly 50-minute sessions targeting
intolerance of uncertainty via procedures such as problem-solving training and imaginal
exposure. Participants randomized to the experimental condition will receive 10 minutes of
computerized interpretation modification training prior to each CBT session. In
interpretation modification training, respondents learn to endorse benign combinations and
reject negative combinations of sentences and words, thus promoting new associative learning.
Participants in the control condition will receive 10 minutes of non-active training, in
which each sentence is paired with a word that is unrelated to the sentence or a word that is
related to a non-threatening (and typically peripheral) aspect of the sentence. Measures of
GAD symptoms, psychopathology, cognitive vulnerability, and interpretation style will be
administered at pre-, mid-, and post-treatment, as well as at 6- and 12-month follow-ups. The
proposed study will provide information about the efficacy, clinical usefulness, and
mechanisms of interpretation modification training in combination with CBT. Given previous
findings on the key role of negative interpretation style in anxiety, the proposed study has
the potential to increase our understanding and ability to treat individuals with GAD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 | |
Completed |
NCT00620776 -
Combined Treatment for Generalized Anxiety Disorder (GAD)
|
Phase 2 |